SCHEMBL23723586

SCHEMBL23723586

CNCC(=O)N(C)c1ccccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
TSHR P16473 1/20 0.44
TP53 P04637 1/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.40
GAA P10253 2/20 0.40
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14873196 0.82 TP53 (0.44) ALDH1A1TSHRTP53DDB1CRBN
SCHEMBL26525031 0.81 TRPM8 (0.43) ALDH1A1TSHRTP53GPBAR1SLC6A2
SCHEMBL307587 0.81 ALDH1A1 (0.43) ALDH1A1TSHRTP53DDB1CRBN
SCHEMBL10224328 0.81 ALDH1A1 (0.43) ALDH1A1TSHRTP53DDB1CRBN
SCHEMBL11339370 0.81 ALDH1A1 (0.44) ALDH1A1TSHRTP53DDB1CRBN
SCHEMBL13684202 0.81 ALDH1A1 (0.47) ALDH1A1TSHRTP53DDB1CRBN
SCHEMBL30120664 0.80 GPBAR1 (0.44) ALDH1A1GPBAR1SLC6A2POLBMEN1
SCHEMBL14839607 0.80 ALDH1A1 (0.42) ALDH1A1TSHRTP53DDB1CRBN
SCHEMBL23723510 0.80 GPBAR1 (0.44) ALDH1A1GPBAR1SLC6A2POLBMEN1
SCHEMBL23723515 0.79 ALDH1A1 (0.43) ALDH1A1TSHRTP53DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
CN-115397423-A Combination therapy for the treatment of MPS1 增益治疗股份有限公司 2022-11-25 CN disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 ALDH1A1 796/4885TSHR 1442/4885TP53 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.